Benitec Biopharma Inc [BNTC] stock prices are up 0.69% to $13.05 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BNTC shares have gain 20.95% over the last week, with a monthly amount drifted -0.15%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on December 16, 2024, and set its price target to $28. On December 13, 2024, Robert W. Baird initiated with an Outperform rating and assigned a price target of $30 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $35 on October 16, 2024. Guggenheim initiated its recommendation with a Buy and recommended $17 as its price target on September 12, 2024. Leerink Partners started tracking with an Outperform rating for this stock on July 22, 2024, and assigned it a price target of $13. In a note dated June 13, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $30 on this stock.
The stock price of Benitec Biopharma Inc [BNTC] has been fluctuating between $9.70 and $17.15 over the past year. Currently, Wall Street analysts expect the stock to reach $27.67 within the next 12 months. Benitec Biopharma Inc [NASDAQ: BNTC] shares were valued at $13.05 at the most recent close of the market. An investor can expect a potential return of 112.03% based on the average BNTC price forecast.
Analyzing the BNTC fundamentals
Gross Profit Margin for this corporation currently stands at 0.16% with Operating Profit Margin at -82.33%, Pretax Profit Margin comes in at -75.22%, and Net Profit Margin reading is -75.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.46 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.70 points at the first support level, and at 12.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.36, and for the 2nd resistance point, it is at 13.67.
Ratios To Look Out For
It’s worth pointing out that Benitec Biopharma Inc [NASDAQ:BNTC]’s Current Ratio is 46.95. Further, the Quick Ratio stands at 46.95, while the Cash Ratio is 46.66.
Transactions by insiders
Recent insider trading involved SUVRETTA CAPITAL MANAGEMENT, L, Director, that happened on Dec 22 ’25 when 19542.0 shares were purchased. Director, SUVRETTA CAPITAL MANAGEMENT, L completed a deal on Dec 19 ’25 to buy 16384.0 shares. Meanwhile, Director SUVRETTA CAPITAL MANAGEMENT, L bought 10215.0 shares on Dec 18 ’25.
